8 results about "Genetic modulation" patented technology

Compositions and methods including stromal cells that have been genetically engineered to knock down or silence one or more genes are disclosed herein. The compositions include a population of isolated stromal cells that have been genetically engineered to reduce or eliminate expression one or more genes which confers permissivity to invasion (referred to herein as INVGOI) in fibroblasts, or cancer associated fibroblasts (CAFs). The cell compositions can be administered to a subject in need thereof to reduce or eliminate expression of one or more genes which confer permissivity to cancer invasion. Alternatively, inhibitory functional nucleic acids which specifically target one or more INV-GOI can be administered to a subject to treat cancer and in additional to chemotherapy, to sensitize cancer cells to chemotherapy.

Described herein are systems and methods for modulating gene expression. Also described herein are systems and methods for treating a disease or a condition by modulating gene expression.

Described herein are systems and methods for modulating gene expression. Also described herein are systems and methods for treating a disease or a condition by modulating gene expression.

A novel gene modulation technique for modulating target nucleic acid and / or protein levels in cells, tissues, organisms and animals is disclosed. The new technology provides compositions for gene modulation applications, including prevention and treatment of human diseases. The composition comprises a short antisense RNA (asRNA) molecule having at least one deoxynucleotide monomer spacer motif. The invention further provides methods of using the compositions to modulate the expression or function of a target gene, to treat or prevent disease, and for biomedical research, disease diagnosis, and other biological applications.

Described herein are systems and methods for modulating gene expression. Also described herein are systems and methods for treating a disease or a condition by modulating gene expression.

The present disclosure relates to compositions including or obtained from genetically modified bacterial host cells (e.g., E. colt) and methods for using the same for cell-free bacteriophage synthesis (CFBS). In particular, the present technology relates to genetically modified E. coli that overexpress one or more of translation initiation factor IF-3 (infC), OxyS and CyaR and / or repress RecC subunit exonuclease RecBCD, and methods for using the same to obtain improved CFBS yields.

Disclosed are abasic modification structures that can be incorporated into oligonucleotides to effectively modulate the expression of a target gene in a subject while mitigating off-target specificity. Also disclosed are gene modulators and pharmaceutical compositions comprising the abasic modification structures, as well as methods of using the structures to modulate the expression of a target gene while mitigating off-target specificity.

To provide pharmaceutical compositions for synergistically modulating microtubule associated protein tau (MAPT) gene expression in a cell.SOLUTION: A pharmaceutical composition comprises: a first genetic modulator which comprises a first DNA-binding domain that binds to a first target site of at least 12 nucleotides in the MAPT gene, and a first transcriptional regulatory domain or a first nuclease domain; and a second genetic modulator which comprises a second DNA-binding domain that binds to a second target site of at least 12 nucleotides in the MAPT gene, and a second transcriptional regulatory domain or a second nuclease domain; where the binding of the first genetic modulator to the first target site and the binding of the second genetic modulator to the second target site results in synergistic repression of MAPT gene expression.SELECTED DRAWING: Figure 13